CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa
about
Data needs for evidence-based decisions: a tuberculosis modeler's 'wish list'Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challengeScaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysisCost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South AfricaPoint-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysisAntibodies against Mycobacterial proteins as biomarkers for HIV-associated smear-negative tuberculosisRecent Insights into the HIV/AIDS Pandemic.Impact of human immunodeficiency virus and CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South Africa.HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993--2005.Healthcare utilization of patients accessing an African national treatment program.CD4 and viral load dynamics in antiretroviral-naïve HIV-infected adults from Soweto, South Africa: a prospective cohort.Incidence of World Health Organization stage 3 and 4 events, tuberculosis and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases To Evaluate AIDS) East Africa regionaDevelopment, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa.Differentiated Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings: An Economic AnalysisSerological diagnostic assays for HIV-associated tuberculosis in sub-Saharan Africa?Comparative cost and performance of light-emitting diode microscopy in HIV-tuberculosis-co-infected patients.Cost-Effectiveness of Improving Health Care to People with HIV in Nicaragua.Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda.Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysisAn evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS.Comparative effectiveness of HIV testing and treatment in highly endemic regions.Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253.Changing concepts of "latent tuberculosis infection" in patients living with HIV infection.The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South AfricaCommunity viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as preventionInterferon gamma release assays for the diagnosis of latent TB infection in HIV-infected individuals in a low TB burden countryCD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and SwitzerlandThe potential role for probiotic yogurt for people living with HIV/AIDS.Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy.First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa.When to start antiretroviral therapy in resource-limited settings.Impaired degranulation and proliferative capacity of Mycobacterium tuberculosis-specific CD8+ T cells in HIV-infected individuals with latent tuberculosis.
P2860
Q27015848-07022DCB-7F8D-4185-98F4-54E96DCFAE1DQ28088557-10FED6C3-58EF-44E5-989B-FD57570DFABDQ28476684-73E01171-54D8-4916-AF3D-5B8F95B06C68Q28534733-DC756111-93BE-462F-80BB-FA4412EAC5CFQ28543954-4EF69549-16ED-4359-A4B6-30A066C45DB3Q28658322-38B14595-845D-4AE7-B401-A010D14F573CQ30235024-C99F1D6C-C78A-496C-94C3-17227D86457EQ30653441-3AA2B5E4-4D35-4FF3-92A6-8CE44C2D0B2DQ31122070-1A80E5B4-1972-4D6D-96F0-E95B8377F131Q33287043-00F715AF-3686-4FF5-B42D-F39BB9509DF1Q33618548-5D9996BE-51C3-4446-B038-047BA58CE21CQ33624926-E28AB61A-28BC-4AE7-9128-83CCEF92D61BQ33670446-3541B1C4-68A1-4041-82E9-2D49B88FB440Q33737122-DD266587-B30B-4AB1-9A56-CEC943F8F514Q33743476-17597511-39C8-490C-8B89-CE285759FB74Q33754187-E1319EF2-FC41-4A70-AFF3-8C643B90C940Q33757712-D575B5E7-BAEB-4C14-A855-8AE1541384B9Q33795967-5B93EFFE-8A45-42A5-AADB-3B103544DE9CQ33851741-4B760DDA-8E5F-422E-9119-E35D75942033Q33882090-3D7919F7-8DA9-4158-8B25-644EC7071344Q33893797-CBD8488B-6C13-472B-BE99-54F34C2C7482Q33920318-CD8407B3-4F91-4442-96B5-E3E5CF3DA27AQ33950833-8CC0F7BF-FB92-46C1-A26D-F40B36028BE9Q34011244-545A26B2-84A2-4228-804D-F5715A61472CQ34064269-173C33AF-F38E-4AB1-B8C6-3E2515FBF284Q34148865-9FED1B52-7E3B-4E89-B036-F9AEDB85B66DQ34170017-E75F5EE5-8F35-4559-897C-6963297ECA51Q34195493-5765FA97-D9B7-4A1E-B250-4D881AE1AE07Q34418077-BDE31ECF-D291-4278-86EE-A1F3E3152C40Q34423942-965ED50D-E74B-48CF-8844-A1625B1E5B4DQ34519553-70CFBD9A-1791-4ED6-9D39-B4752E185F10Q34575195-AF2BE05C-03F4-44DC-B223-B113E7206446Q34664047-C516970D-4185-4AA1-8265-ED04B6F4244BQ34664128-02B6E44D-67C8-4AA9-BAE4-B255533FE235Q34735093-F91FB967-573E-4114-A230-AB72B770360DQ34748599-52102909-A494-4EE9-9037-A374A5D30279Q34768650-A571D94B-D26F-492D-A108-EF8BFF655FC4Q34776408-1813D8F0-757F-4EA4-B6C4-BAC547AF13B1Q34974260-5920611B-6B9C-4BB9-BDFA-F6253795CE2FQ35152753-0B825495-258A-4E79-B976-21D80F998F09
P2860
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa
description
article
@en
im August 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2006
@uk
name
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa
@en
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa
@nl
type
label
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa
@en
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa
@nl
prefLabel
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa
@en
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa
@nl
P2093
P50
P1476
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa
@en
P2093
Bingxia Wang
Charles B. Holmes
Motasim Badri
Sophia Zilber
Zhigang Lu
P304
P356
10.1097/01.QAI.0000225729.79610.B7
P407
P577
2006-08-01T00:00:00Z